https://www.selleckchem.com/pr....oducts/telacebec-q20
0009) and aTHK (TUN+CTG 0.95±0.41mm; CAF+EMD 0.26±0.28mm; p=0.0013). RES showed superior outcomes (p=0.0533) for TUN+CTG (6.86±2.31) compared to CAF+EMD (4.63±1.99). The study failed to find significant differences related to patient-centred outcomes (TUN+CTG 8.30±2.21; CAF+EMD 7.50±1.51; p=0.1136). Five years after treatment, CTG resulted in better clinical and aesthetic outcomes than CAF+EMD. Increased THK was associated with improved outcomes for RECred and RC. Five years after treatment, CTG resulted in better clinical and ae
Like
Comment
Share
